Arcoma

Arcoma EBITDA Margin

The EBITDA Margin of Arcoma (ARCOMA.ST) as of Nov 18, 2026 is 6.64 %. In the previous year, EBITDA Margin was 13.58 % — a change of -51.12% (lower).

EBITDA Margin

6.64 %

YoY

-51.12%

Last updated:

EBITDA Margin of Arcoma is 2025 6.64 % . EBITDA Margin of Arcoma was 2024 13.58 % . It decreases by -51.12% lower compared to the previous year.

The Arcoma EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
3.15 SEK
Jan 1, 2019
8.79 SEK
Jan 1, 2020
3.62 SEK
Jan 1, 2021
-2.88 SEK
Jan 1, 2022
6.70 SEK
Jan 1, 2023
7.00 SEK
Jan 1, 2024
13.58 SEK
Jan 1, 2025
6.64 SEK
The Arcoma EBITDA Margin history
YEAREBITDA MarginYoY
6.64 %-51.12%
13.58 %+94.07%
7.00 %+4.39%
6.70 %-332.70%
-2.88 %-179.60%
3.62 %-58.85%
8.79 %+179.27%
3.15 %-158.08%
-5.42 %+32.89%
-4.08 %-3,593.15%
0.12 %-97.85%
5.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

EBITDA Margin of Arcoma is 6.64 % in 2025.

EBITDA Margin of Arcoma changed from 13.58 % to 6.64 %, representing a -51.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Arcoma since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Arcoma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Arcoma

All Key Metrics — Arcoma